Table 3 Haematological (NTC CTC, Version 2.0) drug-related adverse events

From: Vinflunine – an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study

 

N =62 a patients

N =221 a cycle

 

Overall incidence

Grade 3

Grade 4

Overall incidence

Grade 3

Grade 4

Haematological

n

%

n

%

n

%

n

%

n

%

n

%

Anaemia

55

88.7

4

6.5

0

0

177

80.1

4

1.8

0

0

Leucopenia

53

85.5

15

24.2

5

8.1

147

66.5

25

11.3

7

3.2

Neutropenia

51

82.3

16

25.8

15

24.2

150

67.9

35

15.8

23

10.4

Thrombocytopenia

21

33.9

3

4.8

0

0

57

25.8

3

1.4

0

0

Febrile neutropenia

2

3.2

2

3.2

0

0

2

0.9

2

0.9

0

0

Infection with G3/4 neutropenia

2

3.2

2

3.2

0

0

2

0.9

2

0.9

0

0

  1. aOne patient was not evaluable for haematological toxicity.
Back to article page